With Divestitures, Schering Gets OK To Buy Rival

By Sara Stefanini

Law360, New York (November 16, 2007, 12:00 AM ET) -- Schering-Plough Corp. received a thumbs up on its $14.4 billion takeover of an Akzo-Nobel NV unit on Friday, after it agreed to sell off certain assets in response to regulatory concerns that the deal could harm competition in the poultry vaccine market.

A day after the Federal Trade Commission lodged a complaint challenging Schering-Plough's bid to buy Akzo-Nobel's Organon BioSciences NV, the regulator announced that the pharmaceutical giant had agreed to divest the rights and assets it needs to develop and sell three types of poultry...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles